Objective: Preterm delivery for preeclampsia or placental insufficiency (PREPI) is a clinical criterion for antiphospholipid syndrome (APS), but no prior prospective studies have used the international classification criteria for APS. Our objective is to determine the proportion of women with PREPI who test positive for aPL using international criteria for antiphospholipid antibody (aPL) assays. Methods: We conducted a prospective, case-control study of 148 women delivered < 36 weeks because of PREPI compared to 148 controls. PREPI cases delivered < 36 weeks were compared to matched controls. Cases and controls were tested for aPL. Demographic variables were compared with chi-squared and Wilcoxon-rank-sum statistics. Rates of þ aPL were compared using adjusted odds ratios (aORs) for maternal body mass index (BMI) and Caucasian race. Positive aPL (þaPL) was defined as lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin G (IgG) (GPL) or immunoglobulin M (IgM) (MPL) 40, or anti-b2-glycoprotein I (ab2GPI) IgG (SGU) or IgM (SMU) 40. Results: Controls were more likely to be Caucasian (87% vs 70%, p ¼ 0.006) and had lower BMIs (BMI 26 vs 33, p < 0.001). Positive aPL were found more commonly in cases than controls (11.5% vs 1.4%, aOR 8.9 (95% CI 1.9-41.4)). In þ aPL cases, 76% had þ LA, 41% had þ aCL, and 24% had þ ab2GPI. Conclusion: Women requiring early delivery for PREPI are more likely to have aPL (and thus APS) than controls. This is the first prospective study using both obstetric definitions and laboratory criteria in accordance with APS international criteria. Lupus (2018Lupus ( ) 27, 1903Lupus ( -1910 
Introduction
Antiphospholipid syndrome (APS) is a disorder of concern to obstetricians, rheumatologists, and hematologists. Modified Sapporo classification criteria for APS include specified levels of at least one antiphospholipid antibody (aPL) and at least one clinical criterion. 1 Clinical criteria include vascular thrombosis and/or pregnancy morbidity. Pregnancy morbidity includes one or more unexplained fetal deaths, one or more premature births due to preeclampsia or placental insufficiency (PREPI), and/or three or more unexplained, consecutive early pregnancy losses. 1 PREPI occurring prior to term is typically associated with abnormal placental function. In severe cases, the treatment of PREPI is delivery, which in preterm cases may result in neonatal morbidity.
The pathogenesis of PREPI is multifactorial, but some proportion of cases are caused by maternal aPL. Both case-control and cohort studies report associations between aPL and PREPI. However, previous studies used widely variable definitions of PREPI, and many included women who developed PREPI at term. These studies also used various thresholds to define positive levels of aPL. Many included women with only low positive titers, which would not meet modified Sapporo criteria for APS. Also, few studies repeated testing to confirm aPL, as recommended to make the diagnosis of APS. Finally, small numbers of patients in most previous studies make it difficult to determine the true frequency of aPL in the setting of preterm PREPI. Knowing the prevalence of aPL in women with PREPI would help practitioners understand the true utility of aPL testing in women with preterm PREPI.
The Obstetric task forces at the 14th and 15th International Congress on Antiphospholipid Antibodies noted that high-quality studies defining the association of aPL with pregnancy morbidity are lacking. 34 Thus, our objective was to prospectively measure the association of aPL with the APS obstetric criterion of preterm delivery due to PREPI.
Materials and methods

Study design and participants
We conducted a case-control study comparing frequency of aPL presence in women with and without delivery prior to 36 weeks for PREPI. Cases were women who were delivered prior to 36 0/7 weeks' gestation because of either preeclampsia with severe features or placental insufficiency. All women delivering at University of Utah, Salt Lake City, Utah, or Intermountain Medical Center, Murray, Utah, from February 2014 until May 2017 were eligible for participation. No individuals were excluded on the basis of chronic medical condition or use of any specific medication during pregnancy, including use of aspirin or heparin. Women with multiple gestations were excluded. Women with intellectual disability and incarcerated women were excluded. Gestational age was determined using standard recommendations per the American Congress of Obstetricians and Gynecologists (ACOG). 35 Last menstrual period (LMP) was used to establish the estimated due date (EDD) and was considered consistent with ultrasound dating if the dates were within five days prior to 9 0/7 weeks, within seven days from 9 0/7-15 6/7 weeks, and within 10 days if from 16 0/7 weeks-21 6/7 weeks. If ultrasound assessment of EDD was not consistent with LMP, the EDD was then based on the discrepant ultrasound.
The study was approved by institutional review boards (IRBs) at the University of Utah and Intermountain Healthcare and written informed consent was obtained from all participants. Consent documents were available in English and Spanish, thus, women who did not speak these languages were also excluded.
Case and control definitions
Cases were women delivered at or before 36 weeks' gestation because of preeclampsia with severe features or placental insufficiency (PREPI). We chose delivery at 36 weeks' or earlier as our gestational age criterion for case definition because women without severe features would not be delivered until 37 weeks, thus clearly delineating severe disease. Our goal was to be inclusive of severe presentations of PREPI. However, the international classification criteria for APS use PREPI prior to 34 weeks' gestation, thus, we repeated the analysis of aPL presence using only cases who delivered prior to 34 weeks and their matched controls. We believe both are valuable as 34 weeks is in accordance with international classification criteria, yet 36 weeks is more inclusive of clinical practice and the true spectrum of disease.
Preeclampsia with severe features was defined per ACOG criteria. 36 Women were diagnosed with preeclampsia with severe features if they had new-onset elevated blood pressure (with systolic blood pressure greater than 140 mmHg and/or diastolic blood pressure greater than 90 mmHg) or acute worsening of chronic blood pressure, with or without proteinuria, and with presence of one or more severe feature. Severe features included systolic blood pressure greater than 160 mmHg and/or diastolic blood pressure greater than 110 mmHg, platelet count < 100,000/ml, liver enzymes twice normal concentration or symptoms of liver failure, right upper quadrant or epigastric pain, serum creatinine >1.1 mg/dl, pulmonary edema, and/or new-onset cerebral or visual disturbances.
Placental insufficiency was defined according to the international consensus for the diagnosis of APS:
1 delivery due to fetal growth restriction (FGR) with estimated fetal weight less than the 10th percentile or abdominal circumference less than the fifth percentile for gestational age, oligohydramnios with amniotic fluid index < 5 cm or deepest vertical pocket < 2 cm, abnormal Doppler velocimetry suggestive of fetal hypoxemia (absent or reversed end diastolic flow), abnormal non-stress test, positive contraction stress test, or biophysical profile score <6.
Controls were women with ongoing pregnancies without PREPI at time of enrollment. Pregnant controls were matched to cases based on (a) gestational age within one week at time of first sample draw, (b) maternal age within five years, and (c) parity. Research staff surveyed labor and delivery daily logs and approached women meeting case criteria. Controls were recruited during their scheduled obstetric clinic visits at participating institutions. Women were eligible for participation if they received medical care at one of the participating institutions and had a singleton pregnancy.
Patients were not involved in the design of the study or the analysis/interpretation of the findings. Core outcome sets are not available for the outcome of aPL.
Laboratory definitions and assay characteristics
The primary exposure evaluated was presence or absence of aPL. Presence of aPL was defined as any single positive antiphospholipid test, including lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin G (IgG) (GPL) or immunoglobulin M (IgM) (MPL) > 40, and anti-b2-glycoprotein I (ab2GPI) IgG (SGU) or IgM (SMU) > 40. Although a single positive test is sufficient to meet criteria for aPL presence, an individual may test positive for multiple aPL in combination. Thus, our secondary exposure evaluated was each individual aPL test. Every participant with positive aPL testing was contacted for repeat testing at 12 weeks or greater after initial positive test.
At time of consent, routine venipuncture was performed to obtain samples of peripheral blood for serum and plasma. Laboratory testing was performed at ARUP Laboratories (a National Reference Laboratory) by an experienced technician who was blinded to the samples' status as cases or controls. LA testing was performed according to the updated guidelines of the International Society on Thrombosis and Hemostasis 37 on a STA-R automated coagulation analyzer. Screening on platelet-poor citrated plasma used two different clotting assay principles: a sensitive activated partial thromboplastin time (aPTT) and dilute Russell's viper venom time (dRVVT), each performed according to the manufacturer's recommendations. If one or both screening tests was prolonged, a mixing study was performed using a 1:1 mix of patient sample and pooled normal plasma, followed by repeat testing of the aPTT and/or the dRVVT clotting time without incubation. Results from mixing studies that failed to correct to within the local cutoff values, and thus suggested an inhibitory effect, underwent reflexive confirmation (neutralization) testing to demonstrate aPL dependency by increasing the concentration and/or composition of aPL. Hexagonal phase assay with increased phospholipid was used when mixing studies for aPTT or dRVVT showed an inhibitory effect, but the confirmatory steps were negative. PTT heparin neutralization is performed to account for potential heparin effect. LA was considered present when one or more of the clotting assays was positive (i.e. prolonged aPTT or dRVVT in mixing studies with positive confirmatory testing or positive hexagonal phase in the case of negative confirmatory testing).
Analysis and statistics
Participant medical history, obstetric characteristics, and delivery information were obtained using a combination of interview and chart abstraction. Diagnosis of small for gestational age (SGA) was made using recorded birthweight and standardized birth tables from Oken et al. in which data from the 1999 and 2000 National Center for Health Statistics Natality Data Sets were used to generate a nearly continuous reference measure for gestational age birthweight. 38 SGA was defined as birthweight less than the 10th percentile for gestational age. All data were de-identified and stored in a secure REDCap database. 39 Data analysis was performed using Stata v13.1 (StataCorp LP, College Station, TX). Univariate analysis used student t test, Wilcoxon-rank sum test (if variable was not normally distributed), chisquared test, or Fisher exact test as appropriate. Normality was assessed using the Shapiro-Wilk test. Odds ratios (ORs) were calculated for presence of positive aPL test. ORs were adjusted (aORs) using multivariable logistic regression with a model including the potential confounders maternal body mass index (BMI) and Caucasian race. Cases underwent a secondary nested case-control analysis comparing demographic and obstetric factors between þaPL cases and -aPL cases. We predicted we would detect aPL in 7.9% of cases and 0.5% of controls based on the previous literature. 8, 10, 14, 18 Thus, we estimated needing 140 participants per group to achieve 80% power to detect a difference with a two-sided alpha of 0.05.
Results
Out of 1590 women delivering prior to 36 weeks, 295 were delivered because of PREPI, and 148 of these consented to participate in this study (Figure 1) . A total of 148 women with PREPI indicated delivery prior to 36 weeks were compared to 148 matched controls. Demographics for cases and controls are shown in Table 1 . Cases were less likely to be Caucasian, more likely to be obese, and more likely to have had a previous pregnancy loss.
Overall, 137 had a BMI at the time of delivery of greater than or equal to 30 (46.3%). Concomitant use of heparin or low molecular-weight heparin (LMWH) was more frequent in cases than controls (18.2% vs 0%, p < 0.001). There was only one case of therapeutic LMWH use; the remainder was prophylactic dosing, typically 40 units of LMWH subcutaneous daily. Additionally, cases were delivered at an earlier gestational age (32.9 vs 39.4 weeks, p < 0.001) and were more likely to deliver an SGA neonate (44.9% vs 9.7%, p < 0.001). Despite being matched for overall parity, pregnancy histories differed between groups. Cases were more likely to have experienced any pregnancy loss (31.3% vs 16.4%, p ¼ 0.003) and early pregnancy loss (26.5% vs 12.3%, p ¼ 0.002). Other characteristics were similar and are shown in Table 1 . Table 2 demonstrates aPL results in cases and controls. Overall, there were more women with þaPL in the PREPI case group (11.5% vs 1.4%, aOR 8.9, 95% confidence interval (CI) 1.9-41.4). Individual aPL that were more common in the PREPI group included LA (11.5% vs 1.4%, aOR 7.0, 95% CI 1.5-33.8), and aCL (8.8% vs 1.4%, p ¼ 0.004). LA was the most common aPL detected, and was the only positive lab test detected in the control group. When the cutoff for a positive immunoassay titer was lowered to 20 U/ml, þ aPL remained more common in the PREPI group (14.2 vs 3.4%, aOR 4.3, 95% CI 1.5-12.5), and ab2GPI was more common individually (Table 2 ). There was no difference in frequency of þaPL based on type of case (preeclampsia vs placental insufficiency), with 10 (11.8%) severe preeclampsia cases and seven (11.3%) placental insufficiency cases testing positive for aPL (p ¼ 0.929). There were five cases both with severe PREPI and þaPL.
Of the 19 women with þ aPL, 10 returned for repeat testing. Of those, eight (80%) remained positive. One participant had completely negative testing on repeat, and one who originally was positive for LA retested negative for LA but had an aCL IgM elevated at 26.8 U/ml. Details of each participant with þaPL are shown in Table 3 , including repeat testing.
We performed an analysis of frequency of positive LA based on use of heparin or LMWH. Positive LA was more common in women using heparin or LMWH than in those not using heparin (18.5% vs 3.7%, p ¼ 0.001). At time of confirmatory testing, no women were using heparin or LMWH. Of the five women using heparin or LMWH who originally tested positive for LA, four had confirmatory positive LA testing and one did not complete testing.
Limiting analysis to deliveries prior to 34 weeks excluded 50 cases and their controls (n ¼ 98 PREPI cases prior to 34 weeks). Positive aPL were noted in 10.2% of cases less than 34 weeks and 1.0% of their controls, with aOR of 13.0 (95% CI 1.5-110.3). When demographic and obstetric factors were compared between cases with -aPL and cases with þaPL, the only difference was an increased frequency of history of stillbirth in cases with þaPL (17.7% vs 0.8%, p ¼ 0.005) (data not shown). 
Discussion
Main findings
We found that 11.5% or one out of every nine women with PREPI requiring preterm delivery had presence of aPL. This was considerably more than the 1.4% of women with uncomplicated pregnancies. We were also able to demonstrate repeatedly positive tests in 80% of those who underwent repeat testing.
Interpretation
Two meta-analyses summarized studies assessing the association of aCL and PREPI. 2), and ab2GPI was associated with preeclampsia in cohort studies (OR 19.14, 95% CI 6.34-57.77). Although these associations suggest a link between preeclampsia, placenta insufficiency, and aPL, study inclusion criteria and outcomes are heterogeneous. Many studies used low thresholds for aCL and ab2GPI (>5 GPL/MPL or SGU/ MPU). Of the 28 studies included, only 13 tested for LA and six tested for ab2GPI. Very few studies included repeat testing. Severe disease and premature delivery were not part of the outcome measures.
These epidemiologic findings are consistent with findings in animal studies. Murine studies of the effects of aPL have found complement mediated fetal injury in APS [40] [41] [42] [43] [44] and increased expression of tissue factor. 45 Placentas from human pregnancies affected by APS also show increased complement deposition. 40, 46 Thus, complement activation is a plausible pathway through which aPL leads to adverse pregnancy outcomes.
Strengths and limitations
Our study has numerous strengths. We have a clearly defined phenotype of PREPI that results in need for preterm delivery-a group of women with severe disease. Focusing on these pregnancies allows for a more precise measure of association with aPL. We also measured all relevant aPL, as defined by the modified Sapporo criteria. Many prior studies excluded LA or ab2GPI, which precludes true assessment of aPL prevalence in this population. We also made a rigorous attempt to obtain repeat testing for women who tested positive for aPL, although we were successful in achieving repeat testing in only approximately one-half of women with initial presence of aPL. Relevant levels of aPL persisted in 80% of women undergoing repeat testing.
There is some concern about whether use of heparin or LMWH can result in false-positive LA. Although we did find a higher rate of positive LA in women using heparin or LMWH, the majority (81.5%) of women using heparin or LMWH had a negative LA result. Additionally, four out of five women in our study who were using heparin or LMWH at time of initial positive LA ultimately had positive LA confirmed when no longer using heparin or LMWH. We suspect the initial higher rate of positive LA in women using heparin or LMWH simply reflects appropriate medical care in the setting of increased thrombosis risk.
One of our limitations was our modest success at obtaining repeat testing. Although we made concerted efforts to obtain repeat testing, ultimately only 52.6% of aPL-positive women were willing to complete this. We believe it is clinically relevant for researchers and clinicians to pursue repeat, confirmatory testing, but we acknowledge the obstacles to successfully completing it. Additionally, we used a more liberal definition of preterm than the modified Sapporo criteria (36 as opposed to 34 weeks). We believe this is appropriate because obstetric management of PREPI at these gestational ages is similar. Inasmuch as seven of our cases were >34 weeks (though all less than 36 weeks), one might argue for reconsidering the <34-week threshold for considering the diagnosis of APS. 1 The two cases of PREPI with transiently positive levels of aPL illustrate the need for repeat testing. It is unclear if these women truly have APS or whether treatment will improve obstetric outcomes in subsequent pregnancies. More data are needed regarding the prognosis for women with transiently positive levels of aPL.
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Conclusion
Our findings confirm the association between preterm PREPI and aPL. In our population, the prevalence of aPL in preterm PREPI was 11.5%, or one in nine. This is common enough to support routine testing for aPL when delivering a patient <36 weeks' gestation because of PREPI. However, the utility of an APS diagnosis, or any diagnosis, hinges on our ability to use that information to improve future health outcomes, and well-designed studies to show that treatment, for example, with a heparin agent and/or low-dose aspirin improve pregnancy outcomes in women with APS diagnosed on the basis of PREPI are lacking. Our findings emphasize the importance of working to develop therapy that can be targeted to this population to improve both maternal and neonatal health outcomes.
